1. bookVolume 56 (2022): Issue 1 (January 2022)
Journal Details
License
Format
Journal
eISSN
1336-0329
First Published
30 Mar 2016
Publication timeframe
4 times per year
Languages
English
access type Open Access

Predictive value of the glycated albumin versus glycosylated hemoglobin in follow-up of glucose homeostasis in hemodialysis-maintained type-2 diabetic patients

Published Online: 18 Feb 2022
Volume & Issue: Volume 56 (2022) - Issue 1 (January 2022)
Page range: 10 - 21
Journal Details
License
Format
Journal
eISSN
1336-0329
First Published
30 Mar 2016
Publication timeframe
4 times per year
Languages
English
Abstract

Objectives. Markers for glucose control in hemodialysis patients (HDP) are debated. Glycosylated hemoglobin (HbA1c%) relies on the stable red blood cell survival. Albumin turnover is faster than hemoglobin. Glycated albumin (GA%) may be used as an index of short-term glycemic control. The predictive value of GA% versus HbA1c% in monitoring the glucose homeostasis in type-2 diabetic HDP is studied.

Methods. Forty type-2 diabetic HDP and 20 healthy non diabetic subjects matched age and sex as a control group were included. Calculation of body mass index and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and urea reduction ratio were done. Glycosylated hemoglobin, glycated albumin, fasting blood glucose, insulin, total lipid, kidney and liver functions tests, hepatitis markers, electrolytes, complete blood count, and international normalized ratio were performed. Patients were followed up after 6 months.

Results. The study showed that GA% is more sensitive than HbA1c%, but less specific in the follow-up of the glucose homeostasis in type-2 diabetic HDP. Diagnostic accuracy is higher in HbA1c% than in GA%. HOMA-IR is superior regarding the sensitivity and the diagnostic accuracy.

Conclusion. The present data show that GA% is more sensitive than HbA1c% and has more diagnostic accuracy in the follow-up of the glucose homeostasis in type-2 diabetic HDP.

Keywords

Abe M, Hamano T, Hoshino J, Wada A, Nakai S, Masakane I. Rate of the “burnt-out diabetes” phenomenon in patients on peritoneal dialysis. Diabetes Res Clin Pract 143, 254–262, 2018.10.1016/j.diabres.2018.07.026 Search in Google Scholar

Abe M, Hamano T, Hoshino J, Wada A, Nakai S, Masakane I. Glycemic control and survival in peritoneal dialysis patients with diabetes: A 2-year nationwide cohort study. Sci Rep 9, 3320, 2019.10.1038/s41598-019-39933-5 Search in Google Scholar

American Diabetes Association. 1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2018. Diabetes Care 41, S7–S12, 2018.10.2337/dc18-S001 Search in Google Scholar

Aramwit P, Satirapoj B. Chapter 8. Glycemic control in diabetic patients on long-term maintenance dialysis. In Hemodialysis (Ed. Hiromichi Suzuki), InTechOpen Limited, London, United Kingdom, pp.153–191, 2013.10.5772/52479 Search in Google Scholar

Buell C, Kermah D, Davidson MB. Utility of A1C for diabetes screening in the 1999-2004 NHANES population. Diabetes Care 30, 2233–2235, 2007.10.2337/dc07-0585 Search in Google Scholar

Campbell AK. Detection and quantification of chemiluminescence. In Chemiluminescence principles and applications in biology and medicine (Ed. Ellis Horwood), Chichester, pp. 68–126, 1988. Search in Google Scholar

Cefalu WT, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE. Response to Comment on Cefalu et al. Update and next steps for real-world translation of interventions for type 2 diabetes prevention: Reflections from a diabetes care Editors’ Expert Forum. Diabetes Care 39, 1186–1201, 2016. Diabetes Care 40, e23–e24, 2017.10.2337/dci16-0036 Search in Google Scholar

Chen CW, Drechsler C, Suntharalingam P, Karumanchi A Christoph Wanner C, Berg AH. High glycated albumin and mortality in persons with diabetes mellitus on hemodialysis. Clin Chem 63, 477–485, 2017.10.1373/clinchem.2016.258319 Search in Google Scholar

Cohen MP, Hud E. Measurement of plasma glycoalbumin levels with a monoclonal antibody based ELISA. J Immunol Methods 122, 279–283, 1989.10.1016/0022-1759(89)90275-5 Search in Google Scholar

Divani M, Georgianos PI, Didangelos T, Iliadis F, Makedou A, Hatzitolios A, Liakopoulos V, Grekas DM. Comparison of glycemic markers in chronic hemodialysis using continuous glucose monitoring. Am J Nephrol 47, 21–29, 2018.10.1159/00048584329275415 Search in Google Scholar

Dozio E, Corradi V, Proglio M, Vianello E, Menicanti L, Rigolini R, Caprara C, de Cal M, Corsi Romanelli MM, Ronco C. Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D). Diabetes Res Clin Pract 140, 9–17, 2018.10.1016/j.diabres.2018.03.01729596954 Search in Google Scholar

Freedman BI. A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: time to dispense with the hemoglobin A1C in end-stage kidney disease. Diabetes Care 35, 1621–1624, 2012.10.2337/dc12-0027337961422723586 Search in Google Scholar

Fukami K, Shibata R, Nakayama H, Yamada K, Okuda S, Koga M. Serum albumin-adjusted glycated albumin reflects glycaemic excursion in diabetic patients with severe chronic kidney disease not treated with dialysis. J Diabetes Complications 29, 913–917, 2015.10.1016/j.jdiacomp.2015.06.00326164356 Search in Google Scholar

Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H, Schaefer EJ, Hayashi J. Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS). Diabetologia 54, 3028–3036, 2011.10.1007/s00125-011-2310-621947435 Search in Google Scholar

Hayashi A, Takano K, Masaki T, Yoshino S, Ogawa A, Shichiri M. Distinct biomarker roles for HbA1c and glycated albumin in patients with type 2 diabetes on hemodialysis. J Diabetes Complications 30, 1494–1499, 2016.10.1016/j.jdiacomp.2016.08.01527614726 Search in Google Scholar

Inoue K, Goto A, Kishimoto M, Tsujimoto T, Yamamoto-Honda R, Noto H, Kajio H, Terauchi Y, Noda M. Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other diseases. Clin Exp Nephrol 19, 1179–1183, 2015.10.1007/s10157-015-1110-6467978025824109 Search in Google Scholar

Kobayashi H, Abe M, Yoshida Y, Suzuki H, Maruyama N, Okada K. Glycated albumin versus glycated hemoglobin as a glycemic indicator in diabetic patients on peritoneal dialysis. Int J Mol Sci 17, 619, 2016.10.3390/ijms17050619488144527120597 Search in Google Scholar

Koga M, Inada S, Nakao T, Kawamori R, Kasayama S. The glycated albumin (GA) to HbA1c ratio reflects shorter-term glycemic control than GA: Analysis of patients with fulminant type 1 diabetes. J Clin Lab Anal 31, e22023, 2017.10.1002/jcla.22023681687127386821 Search in Google Scholar

Meyer L, Chantrel F, Imhoff O, Sissoko A, Serb L, Dorey F, Fleury D, Smagala A, Kepenekian L, Krummel T, Le Floch JP, Kessler L. Glycated albumin and continuous glucose monitoring to replace glycated haemoglobin in patients with diabetes treated with haemodialysis. Diabet Med 30, 1388–1389, 2013.10.1111/dme.1229423909880 Search in Google Scholar

National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 60, 850–886, 2012.10.1053/j.ajkd.2012.07.00523067652 Search in Google Scholar

Peng F, Xia X, He F, Li Z, Huang F, Yu X. The effect of glycated hemoglobin and albumin-corrected glycated serum protein on mortality in diabetic patients receiving continuous peritoneal dialysis. Perit Dial Int 35, 566–575, 2015.10.3747/pdi.2014.00011459799025395497 Search in Google Scholar

Rhee JJ, Ding VY, Rehkopf DH, Arce CM, Winkelmayer WC. Correlates of poor glycemic control among patients with diabetes initiating hemodialysis for end-stage renal disease. BMC Nephrol 16, 204, 2015.10.1186/s12882-015-0204-4467375326645204 Search in Google Scholar

Sany D, Elshahawy Y, Anwar W. Glycated albumin versus glycated hemoglobin as glycemic indicator in hemodialysis patients with diabetes mellitus: Variables that influence. Saudi J Kidney Dis Transpl 24, 260–273, 2013.10.4103/1319-2442.109568 Search in Google Scholar

Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 27, 1487–1495, 2004.10.2337/diacare.27.6.148715161807 Search in Google Scholar

Weykamp C, John WG, Mosca A, Hoshino T, Little R, Jeppsson JO, Goodall I, Miedema K, Myers G, Reinauer H, Sacks DB, Slingerland R, Siebelder C. The IFCC reference measurement system for HbA1c: a 6-year progress report. Clin Chem 54, 240–248, 2008.10.1373/clinchem.2007.09740218223132 Search in Google Scholar

Yajima T, Yajima K, Hayashi M, Takahashi H, Yasuda K. Serum albumin-adjusted glycated albumin as a better indicator of glycemic control in Type 2 diabetes mellitus patients with short duration of hemodialysis. Diabetes Res Clin Pract 130, 148–153, 2017.10.1016/j.diabres.2017.05.02028641154 Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo